The Effects of a Multivitamin, Multimineral, and Multiantioxidant Supplement on Cardio-Metabolic Risk Biomarkers: A Cross-Sectional Study

摘要

Use of dietary supplements like multivitamins/multiminerals (MVMM) and antioxidant nutrients, is a potentially safe and cost-effective alternative to medications. Dietary supplements-induced health promotion is controversial among available studies, and vast majority studies were done with individual or a subset of dietary supplements. In this study we assessed the effect of a blended supplement (CellSentials), formulated with MVMM and rich phytochemicals antioxidants, on multiple cardio-metabolic risk biomarkers. We recruited 56 subjects (age: 58.8 1.6) with over one year consumption of blended supplements. Common cardio-metabolic risk biomarkers were measured, including systolic and diastolic blood pressure (SBP and DBP), plasma glucose (Glu), total cholesterol (TC), triglycerides (TGs), high-density cholesterol (HDL-C)), low-density cholesterol (LDL-C), TC: HDL ratio, oxidative stress markers gamma-glutamyltransferase (GGT), and inflammation markers white blood cell (WBC) count, and C-reactive protein (CRP). They were compared to the age, gender and race-matched Non-Users from the National Health and Nutrition Examination Survey (NHANES) 2007-2014 (n=769, mean age: 55.6 0.5) by multiple linear and logistic regression analyses. Blended supplements users had significantly lower levels of Glucose (p 0.001), TGs (p0.001), and TC: HDL-C ratio (p0.001), higher level of HDL-C (p=0.008) as well as lower levels of GGT (p=0.002), CRP (p=0.007) and WBC (p=0.002) than NHANES controls. There were no significant differences in SBP, DBP, TC, LDL-C. Correspondingly, blended supplements users had significantly reduced risks of elevated glucose (OR, 0.21; 95% CI, 0.07 - 0.61), ratio of TC: HDL-C (OR, 0.08; 95% CI, 0.02 - 0.31), TGs levels (OR, 0.07; 95% CI, 0.01 - 0.4), and low HDL-C (OR, 0.23; 95%CI, 0.06 - 0.88). These results demonstrated that blended supplement users had healthier pattern in cardio-metabolic biomarkers than control.